Literature DB >> 23440999

Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Alaina J Mooney1, S Mark Tompkins.   

Abstract

Influenza A viruses continue to emerge and re-emerge, causing outbreaks, epidemics and occasionally pandemics. While the influenza vaccines licensed for public use are generally effective against seasonal influenza, issues arise with production, immunogenicity, and efficacy in the case of vaccines against pandemic and emerging influenza viruses, and highly pathogenic avian influenza virus in particular. Thus, there is need of improved influenza vaccines and vaccination strategies. This review discusses advances in alternative influenza vaccines, touching briefly on licensed vaccines and vaccine antigens; then reviewing recombinant subunit vaccines, virus-like particle vaccines and DNA vaccines, with the main focus on virus-vectored vaccine approaches.

Entities:  

Keywords:  HPAI; influenza; influenza A virus; live-attenuated vaccine; pandemic; vaccine; virus vectors

Year:  2013        PMID: 23440999      PMCID: PMC3579652          DOI: 10.2217/fvl.12.122

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  166 in total

1.  Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass.

Authors:  Robert Alcock; Matthew G Cottingham; Christine S Rollier; Julie Furze; Samodh D De Costa; Marian Hanlon; Alexandra J Spencer; Jared D Honeycutt; David H Wyllie; Sarah C Gilbert; Migena Bregu; Adrian V S Hill
Journal:  Sci Transl Med       Date:  2010-02-17       Impact factor: 17.956

2.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

3.  Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

Authors:  J H C M Kreijtz; R Bodewes; G van Amerongen; T Kuiken; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Vaccine       Date:  2006-09-07       Impact factor: 3.641

4.  Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic.

Authors:  A Takada; N Kuboki; K Okazaki; A Ninomiya; H Tanaka; H Ozaki; S Itamura; H Nishimura; M Enami; M Tashiro; K F Shortridge; H Kida
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Authors:  Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.

Authors:  Leo L M Poon; Y H Connie Leung; John M Nicholls; Pin-Yu Perera; Jack H Lichy; Masafumi Yamamoto; Thomas A Waldmann; J S Malik Peiris; Liyanage P Perera
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus.

Authors:  T Horimoto; Y Kawaoka
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Authors:  Mary A Hoelscher; Sanjay Garg; Dinesh S Bangari; Jessica A Belser; Xiuhua Lu; Iain Stephenson; Rick A Bright; Jacqueline M Katz; Suresh K Mittal; Suryaprakash Sambhara
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

9.  Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

Authors:  Jennifer A Schwartz; Linda Buonocore; Anjeanette Roberts; Amorsolo Suguitan; Darwyn Kobasa; Gary Kobinger; Heinz Feldmann; Kanta Subbarao; John K Rose
Journal:  Virology       Date:  2007-05-23       Impact factor: 3.616

10.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more
  5 in total

1.  Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.

Authors:  Alaina J Mooney; Jon D Gabbard; Zhuo Li; Daniel A Dlugolenski; Scott K Johnson; Ralph A Tripp; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

2.  Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Authors:  Armin Hekele; Sylvie Bertholet; Jacob Archer; Daniel G Gibson; Giuseppe Palladino; Luis A Brito; Gillis R Otten; Michela Brazzoli; Scilla Buccato; Alessandra Bonci; Daniele Casini; Domenico Maione; Zhi-Qing Qi; John E Gill; Nicky C Caiazza; Jun Urano; Bolyn Hubby; George F Gao; Yuelong Shu; Ennio De Gregorio; Christian W Mandl; Peter W Mason; Ethan C Settembre; Jeffrey B Ulmer; J Craig Venter; Philip R Dormitzer; Rino Rappuoli; Andrew J Geall
Journal:  Emerg Microbes Infect       Date:  2013-08-14       Impact factor: 7.163

3.  Field effectiveness of highly pathogenic avian influenza H5N1 vaccination in commercial layers in Indonesia.

Authors:  Simson Tarigan; Michael Haryadi Wibowo; Risa Indriani; Sumarningsih Sumarningsih; Sidna Artanto; Syafrison Idris; Peter A Durr; Widya Asmara; Esmaeil Ebrahimie; Mark A Stevenson; Jagoda Ignjatovic
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

Review 4.  Vector-based genetically modified vaccines: Exploiting Jenner's legacy.

Authors:  Bahar Ramezanpour; Ingrid Haan; Ab Osterhaus; Eric Claassen
Journal:  Vaccine       Date:  2016-10-28       Impact factor: 3.641

Review 5.  Virus-vectored influenza virus vaccines.

Authors:  Ralph A Tripp; S Mark Tompkins
Journal:  Viruses       Date:  2014-08-07       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.